Last updated: October 2, 2026
The commercial opportunity for promethazine hydrochloride and dextromethorphan hydrobromide oral solution is primarily formulation-driven. The active ingredients are mature, low-cost small molecules with no meaningful new-molecule exclusivity. Competitive advantage depends on taste masking, sugar and alcohol positioning, preservative selection, dosing convenience, supply reliability, and differentiated packaging.
The principal product is an oral solution containing 6.25 mg promethazine hydrochloride and 15 mg dextromethorphan hydrobromide per 5 mL. It is generally a prescription product in the United States. The formulation is exposed to generic competition, pediatric safety restrictions, excipient tolerability concerns, and limited scope for blocking patents.
What is promethazine hydrochloride and dextromethorphan hydrobromide oral solution?
Promethazine hydrochloride is a phenothiazine derivative with antihistaminic and antiemetic activity. Dextromethorphan hydrobromide is an antitussive. The combination is marketed for temporary relief of cough and upper-respiratory symptoms.
A representative strength is:
| Component |
Amount per 5 mL |
| Promethazine hydrochloride |
6.25 mg |
| Dextromethorphan hydrobromide |
15 mg |
| Dosage form |
Oral solution |
| U.S. regulatory status |
Prescription drug |
| Typical target users |
Adults and children six years and older, subject to product labeling |
| Key pediatric restriction |
Contraindicated in children under two years because of potentially fatal respiratory depression risk |
Product-specific labels can differ in dosing, excipients, alcohol content, colors, flavor systems, and packaging. The FDA label warns about respiratory depression, sedation, impaired alertness, and interactions with central nervous system depressants. Promethazine-containing products require particular attention to pediatric labeling and medication-error prevention (FDA, 2023a).
What excipients are commonly used in promethazine-dextromethorphan oral solutions?
Commercial formulations commonly use a combination of aqueous vehicle, sweetener, viscosity modifier, buffer, preservative, flavor, and color. The exact inactive-ingredient profile differs by manufacturer.
| Excipient function |
Common options |
Commercial purpose |
| Primary vehicle |
Purified water |
Dissolves or disperses active ingredients |
| Sweetener |
Sucrose, sorbitol, sucralose, saccharin sodium |
Masks bitterness and improves adherence |
| Humectant and viscosity modifier |
Glycerin, propylene glycol, sorbitol |
Improves mouthfeel and solubilization |
| Buffer |
Citric acid and sodium citrate |
Controls pH and supports preservative performance |
| Preservative |
Sodium benzoate, parabens |
Controls microbial growth |
| Flavor |
Cherry, grape, berry, mixed fruit |
Masks promethazine and dextromethorphan bitterness |
| Color |
FD&C dyes or dye-free alternatives |
Supports product identification and appearance |
| Chelator |
Disodium edetate, where used |
Can improve preservative robustness and stability |
| Alcohol or cosolvent |
Ethanol, propylene glycol |
Supports solubilization but creates labeling and market constraints |
The commercial formulation challenge is not simply achieving solubility. Promethazine and dextromethorphan both have strong sensory profiles. A technically stable solution can still fail commercially if it has a bitter aftertaste, excessive throat burn, medicinal odor, or poor viscosity.
Which excipient strategy offers the strongest commercial differentiation?
A differentiated excipient strategy should prioritize four attributes: palatability, pediatric usability, broad patient acceptability, and manufacturing robustness.
Sugar-free formulation
A sugar-free product can target patients with diabetes, caregivers seeking lower sugar exposure, and health systems attempting to reduce sugar-containing liquid medicines. Sorbitol, sucralose, saccharin sodium, and high-intensity flavor systems are potential tools.
The main risks are gastrointestinal intolerance from polyols, aftertaste from artificial sweeteners, and lower acceptability among pediatric users. Sorbitol can produce laxative effects at sufficient exposure. A sugar-free formulation should therefore be evaluated for sweetness profile, osmolarity, gastrointestinal tolerance, and storage stability.
Alcohol-free formulation
Alcohol-free positioning has a clear commercial rationale for pediatric use, abstinence-sensitive patients, institutional formularies, and caregivers who avoid ethanol-containing medicines. Removing ethanol can increase formulation difficulty because ethanol may contribute to solubilization, flavor release, and preservative performance.
An alcohol-free platform may require higher glycerin or propylene glycol, a revised pH system, improved flavor masking, or a different active-ingredient manufacturing process. The product should be tested for precipitation, phase separation, preservative effectiveness, and potency over the proposed shelf life.
Dye-free formulation
Dye-free products can address caregiver preference, institutional purchasing policies, and concern about unnecessary colorants. The commercial benefit is strongest when combined with sugar-free and alcohol-free positioning.
The principal drawback is visual differentiation. A colorless or lightly colored solution requires strong labeling, bottle design, and dosing-device controls to reduce product confusion.
Pediatric taste-masked formulation
Taste masking is likely the highest-value excipient opportunity. Promethazine is bitter, and dextromethorphan can leave a persistent medicinal aftertaste. A successful platform could combine:
- A high-intensity sweetener system
- A layered flavor profile rather than a single fruit flavor
- Viscosity adjustment to reduce rapid oral contact
- pH optimization
- Flavor encapsulation or adsorption technology
- Reduced throat irritation
- A calibrated oral syringe rather than a household teaspoon
Taste masking should be measured through trained sensory panels and age-appropriate acceptability studies. The commercial objective is repeat dosing without caregiver resistance or spillage.
What formulation patents could protect this product?
The active ingredients have been known for decades, and their core composition-of-matter protection has expired. The patent opportunity is therefore narrow and likely limited to formulation or delivery improvements.
Potential claim categories include:
- A defined excipient concentration range that improves stability.
- A sugar-free and alcohol-free oral solution with specified pH and preservative performance.
- A taste-masked composition using a defined flavor or encapsulation system.
- A low-viscosity or high-viscosity formulation with improved dose uniformity.
- A preservative-free multidose package using a microbial-barrier closure.
- A unit-dose cup, sachet, or oral-syringe presentation.
- A manufacturing process that prevents precipitation or degradation.
- A combination of pH, buffer, sweetener, and cosolvent parameters that produces a stable solution.
Patent strength would depend on whether the claims cover a genuinely non-obvious formulation or merely recite routine excipients at predictable concentrations. Broad claims covering promethazine, dextromethorphan, water, sweetener, flavor, and preservative would face substantial validity and obviousness risk.
Trade-secret protection may be more practical for flavor ratios, processing order, mixing temperature, and preservative optimization. Such protection does not block an independently developed competing product but can preserve manufacturing advantages.
When does promethazine-dextromethorphan lose exclusivity?
The active ingredients already have fully expired small-molecule exclusivity. There is no remaining new chemical entity exclusivity for promethazine or dextromethorphan.
| Exclusivity category |
Position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not inherent to this combination |
| Pediatric exclusivity |
Product- and indication-specific; not assumed |
| Qualified infectious disease exclusivity |
Not applicable |
| Biosimilar reference-product exclusivity |
Not applicable |
| Formulation exclusivity |
Possible only through product-specific patents or regulatory exclusivity |
| Generic competition |
Established and structurally high |
The principal U.S. market barrier is therefore an approved ANDA, manufacturing capability, and commercial access rather than active-ingredient patent protection.
What is the Orange Book status of promethazine-dextromethorphan oral solution?
The Orange Book lists approved prescription drug products and relevant patent and exclusivity information for reference products. A formulation’s exact Orange Book position depends on the specific NDA, reference-listed drug, and approved strength.
For this product category, the practical conclusions are:
- The combination is a mature prescription product.
- Active-ingredient patents are not the principal barrier.
- Any relevant Orange Book patent would likely concern a specific formulation, method of use, or approved product.
- Generic applicants may rely on Paragraph III, Paragraph IV, or other applicable ANDA certifications depending on the listed patent record.
- A product name alone does not establish a single patent estate because multiple manufacturers may market materially different oral solutions.
The FDA Orange Book should be reviewed at the NDA and strength level before making a product-specific Paragraph IV or launch assessment (FDA, 2024a).
Are Paragraph IV challenges and patent litigation material risks?
Paragraph IV risk is likely secondary to ordinary generic competition unless a formulation patent is listed against a particular reference product. A challenger would need to address the claims of the listed patent, not merely demonstrate that the active ingredients are old.
Potential litigation issues include:
- Obviousness of excipient combinations
- Written-description support for concentration ranges
- Enablement of broad taste-masking claims
- Anticipation by older cough-syrup formulations
- Infringement by equivalent flavor, buffer, or preservative systems
- Patent-term and listing defects
- Noninfringement based on different pH or excipient concentrations
There is no general basis to assume a major patent settlement or launch-blocking litigation campaign for the category. Product-specific litigation cannot be inferred without identifying the relevant NDA, ANDA, patent number, and defendant.
What FDA regulatory requirements affect the formulation strategy?
The product must satisfy the requirements for an approved prescription oral solution, including identity, strength, quality, purity, stability, microbial control, container closure, and dose uniformity.
The most important regulatory issues are:
Pediatric safety
Promethazine is contraindicated in children younger than two years because of respiratory depression risk. Labeling, bottle design, dosing devices, and promotional claims must not imply unrestricted pediatric use.
Oral-solution quality
The manufacturer must control:
- Active-ingredient assay
- Content uniformity across the bottle
- pH
- Specific gravity
- Viscosity
- Microbial limits
- Preservative content
- Degradation products
- Extractables and leachables
- Stability after opening
Inactive ingredients
Each excipient must be acceptable for the proposed route, concentration, and patient population. The FDA Inactive Ingredient Database can support excipient precedent, but prior use in another oral product does not eliminate the need to justify concentration, safety, and product performance (FDA, 2024b).
Packaging and dosing
A calibrated oral syringe can reduce dose errors compared with a household spoon. Child-resistant packaging is commercially relevant because the product can cause serious toxicity in overdose. A bottle, cap, syringe, and labeling system should be assessed as an integrated product rather than separate components.
What commercial opportunities exist for this oral solution?
Branded generic differentiation
The strongest near-term opportunity is a branded generic positioned around:
- Sugar-free composition
- Alcohol-free composition
- Dye-free presentation
- Improved taste
- Oral-syringe dosing
- Smaller bottle sizes
- Tamper-evident and child-resistant packaging
A formulation that combines all four positioning points may command a modest premium if it secures pharmacy, urgent-care, pediatric, and institutional distribution.
Contract manufacturing and private label
The product is suitable for contract development and manufacturing organizations with liquid-dose capabilities. A manufacturer with validated preservative systems, flavor libraries, and pediatric packaging can offer private-label versions to regional pharmacies, wholesalers, and telehealth platforms.
Institutional supply
Hospitals, urgent-care centers, pediatric practices, and long-term-care facilities may value:
- Unit-dose packaging
- Barcoded bottles
- Oral syringes
- Reliable supply
- Standardized concentrations
- Alcohol-free and dye-free options
Institutional buyers are likely to prioritize supply continuity and medication safety over flavor innovation alone.
Geographic expansion
Promethazine-dextromethorphan oral solution has potential in markets where prescription cough medicines remain common, but regulatory treatment varies. Local requirements may affect:
- Promethazine scheduling
- Dextromethorphan controls
- Alcohol limits
- Pediatric labeling
- Approved flavoring agents
- Import and serialization rules
U.S. approval does not automatically support marketing in Canada, Europe, or emerging markets.
How does this product compare with competing cough medicines?
| Product category |
Main advantage |
Main commercial limitation |
| Promethazine-dextromethorphan |
Combines antihistaminic and antitussive activity |
Sedation, pediatric restrictions, prescription status |
| Dextromethorphan-only liquid |
Simpler formulation and broader consumer familiarity |
Less differentiated; abuse concerns |
| Promethazine-codeine |
Strong legacy demand in some markets |
Opioid controls, abuse risk, tighter regulatory scrutiny |
| Brompheniramine-pseudoephedrine-dextromethorphan |
Multi-symptom positioning |
More active ingredients and interaction concerns |
| Benzonatate capsules |
Non-liquid dosage form |
Swallowing and misuse risks; no pediatric liquid positioning |
| Nonprescription cough syrups |
Broad retail access |
High competition and limited prescription-channel differentiation |
The combination’s main competitive advantage is a liquid dosage form with a recognizable prescription profile. Its main disadvantages are sedation, pediatric restrictions, and a crowded generic market.
How strong is the patent estate?
The patent estate is weak at the active-ingredient level and potentially moderate at the formulation level.
| Patent layer |
Relative strength |
| Promethazine composition of matter |
None of commercial significance |
| Dextromethorphan composition of matter |
None of commercial significance |
| Basic combination |
Generally weak |
| Defined oral-solution formulation |
Potentially moderate if technically differentiated |
| Taste-masking technology |
Moderate if supported by comparative data |
| Packaging and dosing system |
Narrow but potentially enforceable |
| Manufacturing process |
Often better protected as a trade secret |
| Method of use |
Limited unless tied to a specific patented indication |
A credible formulation patent should include comparative evidence showing improved stability, palatability, dose uniformity, preservative performance, or patient usability. Routine substitution of sucrose with sorbitol or ethanol with glycerin is unlikely to provide durable blocking power without unexpected results.
What generic launch risks exist?
Generic launch risk is high because:
- The active ingredients are inexpensive.
- The formulation is technically familiar.
- Multiple oral-liquid manufacturers can enter.
- Prescribers often have limited brand loyalty.
- Pharmacy substitution can accelerate share loss.
- Formulation improvements may be difficult to protect broadly.
A differentiated entrant can reduce price erosion through a superior package, supply reliability, and targeted distribution. The commercial case is weaker for an undifferentiated copy sold solely on acquisition cost.
Key Takeaways
- Promethazine hydrochloride and dextromethorphan hydrobromide oral solution is a mature prescription product with no meaningful active-ingredient exclusivity.
- The strongest commercial opportunity is a sugar-free, alcohol-free, dye-free, taste-masked formulation with a calibrated oral syringe.
- Formulation patents may be available but should rely on measurable technical advantages rather than routine excipient substitutions.
- Trade secrets covering flavor systems and manufacturing conditions may have greater practical value than broad composition claims.
- Biosimilar risk is irrelevant because the product contains small-molecule active ingredients.
- Paragraph IV and litigation risk are product-specific and depend on the NDA, reference-listed drug, and any listed formulation patents.
- Generic competition is structurally high, making supply reliability, pediatric usability, packaging, and institutional distribution central to commercial success.
- The most attractive market entry model is a differentiated branded generic or private-label platform rather than an undifferentiated commodity product.
FAQs
Is promethazine-dextromethorphan oral solution available over the counter?
In the United States, the combination is generally marketed as a prescription product. Dextromethorphan-only products may be available without a prescription, but that status does not extend automatically to the combination with promethazine.
Can a sugar-free version obtain separate FDA exclusivity?
A sugar-free formulation does not receive automatic regulatory exclusivity. Protection would generally require an applicable patent, qualifying regulatory exclusivity, or commercial differentiation without formal exclusivity.
Is ethanol necessary in promethazine-dextromethorphan oral solution?
No. Ethanol may support solubilization or preservation in some formulations, but an alcohol-free formulation can be developed through alternative solvent, buffer, preservative, and flavor strategies.
Is dextromethorphan a controlled substance in the United States?
Dextromethorphan is not federally scheduled as a controlled substance, although misuse and abuse concerns affect labeling, packaging, and state-level regulation. Promethazine remains a prescription ingredient in this combination.
What is the most defensible formulation patent strategy?
The strongest strategy is likely a narrowly defined composition or process claim supported by comparative data showing improved taste, stability, preservative effectiveness, or dose uniformity. Broad claims covering conventional syrup excipients are more vulnerable to validity challenges.
References
-
U.S. Food and Drug Administration. (2023a). Promethazine hydrochloride and dextromethorphan hydrobromide oral solution prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. FDA.
-
U.S. Food and Drug Administration. (2006). FDA warns about fatal respiratory depression in children given promethazine. FDA Drug Safety Communication.
-
Code of Federal Regulations. (2024). 21 C.F.R. Part 211: Current good manufacturing practice for finished pharmaceuticals. U.S. Government Publishing Office.
